SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis

NCT00071279 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1215

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Embolism
Deep Vein Thrombosis

Interventions

DRUG: SR34006 (idraparinux sodium) Injection

Sponsor

Sanofi